NEWRON PHARMACEUT. EO-20 - Asset Resilience Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is NEWRON PHARMACEUT. EO-20's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how NEWRON PHARMACEUT. EO-20's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of NEWRON PHARMACEUT. EO-20.
Liquid Assets Composition Over Time
This chart breaks down NEWRON PHARMACEUT. EO-20's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of NEWRON PHARMACEUT. EO-20 for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €16.68 Million | 41.67% |
| Total Liquid Assets | €16.68 Million | 41.67% |
Asset Resilience Insights
- Very High Liquidity: NEWRON PHARMACEUT. EO-20 maintains exceptional liquid asset reserves at 41.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NEWRON PHARMACEUT. EO-20 Industry Peers by Asset Resilience Ratio
Compare NEWRON PHARMACEUT. EO-20's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for NEWRON PHARMACEUT. EO-20 (2009–2025)
The table below shows the annual Asset Resilience Ratio data for NEWRON PHARMACEUT. EO-20.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.67% | €16.68 Million ≈ $19.50 Million |
€40.03 Million ≈ $46.80 Million |
+37.14pp |
| 2024-12-31 | 4.53% | €2.89 Million ≈ $3.38 Million |
€63.91 Million ≈ $74.72 Million |
-19.68pp |
| 2023-12-31 | 24.21% | €6.26 Million ≈ $7.32 Million |
€25.87 Million ≈ $30.24 Million |
-0.93pp |
| 2022-12-31 | 25.14% | €9.35 Million ≈ $10.93 Million |
€37.20 Million ≈ $43.48 Million |
+6.17pp |
| 2021-12-31 | 18.97% | €9.57 Million ≈ $11.19 Million |
€50.49 Million ≈ $59.02 Million |
-16.26pp |
| 2020-12-31 | 35.23% | €18.04 Million ≈ $21.09 Million |
€51.20 Million ≈ $59.86 Million |
+6.85pp |
| 2019-12-31 | 28.38% | €17.11 Million ≈ $20.00 Million |
€60.29 Million ≈ $70.48 Million |
+1.33pp |
| 2018-12-31 | 27.05% | €16.23 Million ≈ $18.97 Million |
€60.00 Million ≈ $70.15 Million |
+0.43pp |
| 2017-12-31 | 26.62% | €19.44 Million ≈ $22.73 Million |
€73.02 Million ≈ $85.37 Million |
+20.40pp |
| 2016-12-31 | 6.22% | €3.52 Million ≈ $4.12 Million |
€56.59 Million ≈ $66.16 Million |
-4.87pp |
| 2015-12-31 | 11.09% | €4.92 Million ≈ $5.75 Million |
€44.38 Million ≈ $51.88 Million |
-7.65pp |
| 2014-12-31 | 18.74% | €6.95 Million ≈ $8.12 Million |
€37.07 Million ≈ $43.34 Million |
+1.48pp |
| 2013-12-31 | 17.26% | €5.46 Million ≈ $6.38 Million |
€31.62 Million ≈ $36.96 Million |
+9.10pp |
| 2012-12-31 | 8.16% | €3.64 Million ≈ $4.26 Million |
€44.65 Million ≈ $52.20 Million |
+4.30pp |
| 2009-12-31 | 3.85% | €1.60 Million ≈ $1.88 Million |
€41.68 Million ≈ $48.73 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more